Sigknow, a Taiwan-based Digital Healthcare Solution provider, has newly received US Food and Drug Administration (FDA) Class II clearance for its Arrhythmia Diagnostic Solution EZYPRO® in June 2022. This is in addition to the full medical device certifications in the Asian and European markets where EZYPRO® is serving.
EYZPRO®, the No. 1 prolonged ECG monitoring solution in Asia, provides healthcare professionals with patented 14-day ECG patch monitor and diagnosis-ready ECG reports fully curated by CRAT-certified ECG analysts.
“Asia has the most diverse climates, from steamy tropical summers to biting cold winters, and hence presents tough challenges for patches. The hypoallergenic waterproof ECG patch monitor of EZYPRO® can accommodate different wear conditions and provide patients with comfortable ECG monitoring experience for 14 days,” said Sigknow CEO Jiayi Lai. “We work closely with cardiologists and healthcare providers around the globe and support doctors with top-notch ECG reports of detailed arrhythmia information. Our ISO information security certified cloud platform assures doctors and nurses of a hassle-free efficient workflow.”
Behind the clinical-ready EZYPRO® Report which supports cardiologists in their arrhythmia diagnosis is a professional ECG analysis team of US CRAT-certified ECG technicians and nurses. Every ECG report is scrutinized by the team before it is released and delivered to Cardiologists. The proprietary ECG AI analysis software embedded with deep learning algorithm brings accuracy and speed to the EZYPRO® reporting service. “Doctors are often impressed by our report quality, from superb ECG tracing, arrhythmias details, to the user-friendly report presentation. EZYPPRO® is cardiologists’ No. 1 choice for arrhythmia diagnosis.”